A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Sponsor
Bristol-Myers Squibb
Study ID
NCT07141563
Status
Completed

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)

Key Dates

Start date
May 26, 2025
Status verified
Jan 2026
Primary completion
Nov 18, 2025
Completion
Nov 18, 2025

Study Design

Enrollment
70 participants (actual)

Arms

  • Arm: Cohort 1
    Participants with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant treatment with nivolumab in combination with platinum-based chemotherapy

Primary Outcome Measure

Rate of pathological complete response (pCR) post-surgery [ Time Frame: Up to 1 year ]

Related Studies